The risk/benefit fallacy
September 01 2007
When the members of the FDA advisory committee voted 22 to 1 to keep Avandia on the market, they had ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.